Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief

Dow Jones

Jan 22, 2025

By Sabela Ojea

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer.

The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant.

As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board.

Borie in the past acted as the founding CEO at Kyverna.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

January 21, 2025 17:17 ET (22:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505738174"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505738174\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505738174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505738174","market":"sg","top_or_hot":-1,"title":"Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> said it named Naji Gehchan as its chief medical and development officer. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant. \n</p>\n<p>\n  As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board. \n</p>\n<p>\n  Borie in the past acted as the founding CEO at Kyverna. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 17:17 ET (22:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyverna Therapeutics Taps Naji Gehchan as Medical and Development Chief\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-22 06:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> said it named Naji Gehchan as its chief medical and development officer. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant. \n</p>\n<p>\n  As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board. \n</p>\n<p>\n  Borie in the past acted as the founding CEO at Kyverna. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 17:17 ET (22:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505738174","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505738174","pubTimestamp":1737497820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer.The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant.As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board.Borie in the past acted as the founding CEO at Kyverna.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KYTX":"Kyverna Therapeutics"},"translate_title":"Kyverna Therapeutics任命Naji Gehchan为医疗和开发主管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYTX":1},"content_text":"By Sabela Ojea \n\n\n \n\n\nKyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. \n\n\n  The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant. \n\n\n  As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board. \n\n\n  Borie in the past acted as the founding CEO at Kyverna. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 17:17 ET (22:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}